Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer

World Journal of Urology

Volumn 28, Issue 3, 2010, Pages 391-398

  Reuter, Christoph W M ^a   Morgan, Michael A ^a   Ivanyi, Philipp ^a   Fenner, Martin ^a   Ganser, Arnold ^a   Grünwald, Viktor ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Carboplatin; Castration resistant; Docetaxel; Docetaxel resistant; Prostate cancer; Salvage chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; TAXOID;

AGED; ARTICLE; BLOOD; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG RESISTANCE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; PROBABILITY; PROSTATE TUMOR; PROSTATECTOMY; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COHORT STUDIES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 77952881651     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0527-5     Document Type: Article

References (30)

1. Shelley M, Harrioson C, Coles B et al (2010) Chemotherapy for hormone-refractory prostate cancer (review). Cochrane Database of systematc reviews 2006. Issue 4. Art. No.: CD005247. doi: 10. 1002/14651858. CD005247. pub2.
2. Garmey EG, Sartor O, Halabi S, Vogelzang NJ (2008) Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol. 6(118-22): 127-132.
3. Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K (2006) First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 106: 1041-1046.
4. Lainakis G, Nikos A, Gerassimos A et al (2008) Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer. Urology 71: 1181-1185.
5. Nelius T, Klatte T, de Riese W, Haynes A, Filleur S (2009) Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol [Epub ahead of print].
6. Caffo O, Sava T, Comploj E et al (2010) Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol Oncol 28: 152-156.
7. Rosenberg JE, Weinberg VK, Kelly WK et al (2007) Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110: 556-563.
8. Rosenberg JE, Ryan CJ, Weinberg VK et al (2009) Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol 27: 2772-2778.
9. Hussain A, DiPaola RS, Baron AD et al (2009) Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 20: 492-497.
10. Hahn NM, Zon RT, Jones T et al (2008) A multicenter phase II study of pemetrexed as second-line chemotherapy for the treatment of hormone refractory prostate cancer (HRPC); Hoosier Oncology Group GU-0367. J Clin Oncol 26(S): 16019.
11. Michaelson MD, Gilligan T, Oh W et al (2005) Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). J Clin Oncol 23(16(S)): 4517.
12. Aragon-Ching JB, Jain L, Gulley JL et al (2009) Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 103: 1636-1640.
13. Dror Michaelson M, Regan MM, Oh WK et al (2009) Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20: 913-920.
14. Oh WK, Tay MH, Huang J (2007) Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 109: 477-486.
15. Sternberg CN, Petrylak DP, Sartor O et al (2009) Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 27: 5431-5438.
16. Regan MM, O'Donnell EK, Kelly WK et al (2009) Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Ann Oncol 21: 312-318.
17. Nakabayashi M, Sartor O, Jacobus S et al (2008) Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int 101: 308-312.
18. Ross RW, Beer TM, Jacobus S et al (2008) Prostate cancer clinical trials consortium. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 112: 521-526.
19. Loriot Y, Massard C, Gross-Goupil M et al (2009) Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 20: 703-708.
20. Sella A, Yarom N, Zisman A, Kovel S (2009) Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. Oncology 76: 442-446.
21. Dorff TB, Groshen SG, Wei D et al (2008) Interim results of a phase II trial of pemetrexed and oxaliplatin as 2nd/3rd line therapy in hormone refractory prostate cancer. J Clin Oncol 26(S): 5139.
22. Scher HI, Halabi S, Tannock I et al (2008) Prostate cancer clinical trials working group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159.
23. Scotté F, Tourani JM, Banu E et al (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23: 4424-4429.
24. Marangolo M, Bengala C, Conte PF et al (2006) Dose and outcome: the hurdle of neutropenia (Review). Oncol Rep 16: 233-248.
25. Reid IR (2009) Osteonecrosis of the jaw: who gets it, and why? Bone 44: 4-10.
26. Budman DR, Calabro A, Kreis W (2002) Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 13: 1011-1016.
27. Cabrespine A, Bay JO, Barthomeuf C et al (2005) In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment. Anticancer Drugs 16: 417-422.
28. Wosikowski K, Lamphere L, Unteregger G et al (2007) Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 60: 589-600.
29. Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W (2002) Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci 59: 1198-1211.
30. Schertl S, Hartmann RW, Batzl-Hartmann C et al (2007) Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies. J Cancer Res Clin Oncol 133: 153-167.